Wockhardt · NSE: WOCKPHARMA · BSE: 532300
Q3 FY21 results · Oct–Dec 2020
Wockhardt reported revenue from operations of ₹764.02 crore (down 12.1% from Q3 FY20) and net profit of ₹32.40 crore (up 68.7% from Q3 FY20) for Q3 FY21 (Oct–Dec 2020), on a consolidated basis.
| Item | Q3 FY21 | Q3 FY20 | YoY | Q2 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 764.02 | 869.15 | −12.1% | 714.05 | +7.0% |
| Other income | 100.54 | 17.20 | +484.5% | 16.24 | +519.1% |
| Total income | 864.56 | 886.35 | −2.5% | 730.29 | +18.4% |
| Profit before tax | 31.19 | 16.42 | +90.0% | (85.11) | Turned profit |
| Net profit for the period | 32.40 | 19.21 | +68.7% | 3.29 | +884.8% |
| Attributable to shareholders of the company | 15.24 | 9.63 | +58.3% | 3.55 | +329.3% |
| EPS, basic (₹) | 1.38 | 0.87 | +58.6% | 0.32 | +331.2% |
| Net margin (%) | 4.2 | 2.2 | 0.5 |
| Item | Q3 FY21 | Q3 FY20 | YoY | Q2 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 252.97 | 328.74 | −23.0% | 294.96 | −14.2% |
| Other income | 9.72 | 19.77 | −50.8% | 14.96 | −35.0% |
| Total income | 262.69 | 348.51 | −24.6% | 309.92 | −15.2% |
| Profit before tax | (90.26) | (86.86) | Loss widened | (87.29) | Loss widened |
| Net profit for the period | (68.67) | (69.84) | Loss narrowed | (57.38) | Loss widened |
| EPS, basic (₹) | (6.20) | (6.31) | Loss narrowed | (5.18) | Loss widened |
| Net margin (%) | -27.1 | -21.2 | -19.5 |
Consolidated
- Filed with BSE
- 29 Jan 2021, 20:04 IST
- Board meeting
- 29 Jan 2021
- Period
- 01 Oct 2020 to 31 Dec 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 29 Jan 2021, 20:04 IST
- Board meeting
- 29 Jan 2021
- Period
- 01 Oct 2020 to 31 Dec 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE